Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Precigen Inc (PGEN)

Precigen Inc (PGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 396,299
  • Shares Outstanding, K 252,420
  • Annual Sales, $ 6,230 K
  • Annual Income, $ -95,900 K
  • 60-Month Beta 1.88
  • Price/Sales 66.10
  • Price/Cash Flow N/A
  • Price/Book 4.03
Trade PGEN with:

Options Overview Details

View History
  • Implied Volatility 123.79% ( -12.29%)
  • Historical Volatility 61.97%
  • IV Percentile 27%
  • IV Rank 8.13%
  • IV High 884.98% on 11/01/23
  • IV Low 56.44% on 12/12/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,170
  • Volume Avg (30-Day) 436
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 18,559
  • Open Int (30-Day) 16,587

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.08
  • Number of Estimates 3
  • High Estimate -0.07
  • Low Estimate -0.10
  • Prior Year -0.08
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3000 +18.85%
on 05/30/24
1.8300 -15.57%
on 06/06/24
+0.1550 (+11.15%)
since 05/20/24
3-Month
1.2000 +28.75%
on 05/10/24
1.8300 -15.57%
on 06/06/24
+0.1050 (+7.29%)
since 03/20/24
52-Week
0.8354 +84.94%
on 11/13/23
1.8799 -17.81%
on 08/30/23
+0.3000 (+24.10%)
since 06/20/23

Most Recent Stories

More News
Precigen to Participate in Upcoming Leading Investor and Industry Conferences

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5550 (-0.96%)
Levi & Korsinsky LLP notifies shareholders of BMRN, MAXR, SYF, PGEN of pending class action settlements

/PRNewswire/ -- Levi & Korsinsky informs shareholders of BMRN, MAXR, SYF, PGEN that a settlement has been reached in a pending class action lawsuit against...

BMRN : 84.43 (+0.33%)
MAXR : 52.99 (+0.02%)
SYF : 44.47 (+1.93%)
PGEN : 1.5550 (-0.96%)
Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

– The FDA confirmed that the ongoing Phase 1/2 single arm study of PRGN-2012 in RRP will serve as the pivotal study to support accelerated approval and no...

PGEN : 1.5550 (-0.96%)
Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

– FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and no additional randomized, placebo-controlled trial will be required to...

PGEN : 1.5550 (-0.96%)
Precigen to Announce Second Quarter and First Half 2023 Financial Results on August 9th

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5550 (-0.96%)
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

/PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the...

PGEN : 1.5550 (-0.96%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – June 8, 2023 – USA News Group  –  By utilizing newly developed novel mechanisms, biotech researchers and scientists are...

ONCY : 1.0095 (-1.03%)
ONC.TO : 1.39 (unch)
GILD : 68.16 (+7.93%)
ITOS : 14.97 (+0.13%)
GSK : 40.97 (+0.05%)
PGEN : 1.5550 (-0.96%)
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action

/PRNewswire/ -- USA News Group - By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against...

ONC.TO : 1.39 (unch)
ONCY : 1.0095 (-1.03%)
GILD : 68.16 (+7.93%)
ITOS : 14.97 (+0.13%)
GSK : 40.97 (+0.05%)
PGEN : 1.5550 (-0.96%)
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies

USA News Group – By utilizing newly developed novel mechanisms, biotech researchers and scientists are making strides in the battle against cancer. A study put out by researchers at the University of...

ONCY : 1.0095 (-1.03%)
ONC.TO : 1.39 (unch)
GILD : 68.16 (+7.93%)
ITOS : 14.97 (+0.13%)
GSK : 40.97 (+0.05%)
PGEN : 1.5550 (-0.96%)
Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients

– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion...

PGEN : 1.5550 (-0.96%)

Business Summary

Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional...

See More

Key Turning Points

3rd Resistance Point 1.7033
2nd Resistance Point 1.6767
1st Resistance Point 1.6233
Last Price 1.5550
1st Support Level 1.5433
2nd Support Level 1.5167
3rd Support Level 1.4633

See More

52-Week High 1.8799
Last Price 1.5550
Fibonacci 61.8% 1.4809
Fibonacci 50% 1.3577
Fibonacci 38.2% 1.2344
52-Week Low 0.8354

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar